Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 47 results for "julie masow"

Johane Masowe Vadzidzi vaJesu: A church at war

At midday, under a clear sky, hundreds of anxious Johane Masowe Vadzidzi VaJesu Church members were milling around Mudzidzi Wimbo's homestead in Madziva's Mutumba village. BY Everson Mushava Members of the Vadzidzi church at Mhukuta's ... Zimbabwe Standard, 2 days ago

Juno Plunges After 3 Patients Die in Trial of Cancer Therapy

Juno Therapeutics Inc. plunged by a record 27 percent after three patients died in a trial for its lead cancer therapy and U.S. regulators put the study on hold, raising questions about the risks and tradeoffs of a new and very aggressive approach ...
 Bloomberg2 weeks ago

Novartis PKC412 (midostaurin) pivotal data published in NEJM show 60% response rate in advanced systemic mastocytosis (SM)

/PRNewswire/ -- Novartis announced today that The New England Journal of Medicine (NEJM) published data for PKC412 (midostaurin) demonstrating an overall response rate, defined as a major or partial response, of 60% (95% confidence interval [CI], ...
 TickerTech.com4 weeks ago

Novartis combination therapy Tafinlar® + Mekinist® demonstrates overall survival benefit at three-year follow-up in patients with advanced melanoma

/PRNewswire/ -- Novartis today announced data from a Phase III study showing a significant survival benefit for patients with BRAF V600E/K mutation-positive advanced melanoma when treated with the first-line combination of Tafinlar® (dabrafenib) + ...
 TickerTech.com1 month ago

Novartis pivotal data for Tafinlar® + Mekinist® demonstrated a 63 percent overall response rate in treating rare form of lung cancer

/PRNewswire/ -- Novartis today announced new data for multiple investigational and established non-small cell lung cancer (NSCLC) treatments, including results from a pivotal, Phase II study of Tafinlar® (dabrafenib) in combination with Mekinist® ...
 TickerTech.com1 month ago

Novartis data show more than 50 percent of eligible Ph+ CML patients maintain Treatment-free Remission (TFR) after stopping Tasigna®

/PRNewswire/ -- Novartis today announced at the 52nd American Society of Clinical Oncology (ASCO) Annual Meeting, the first results from the Tasigna (nilotinib) Treatment-free Remission (TFR) clinical trial program. These studies evaluated the ...
 TickerTech.com1 month ago

Novartis announces US collaboration to co-promote Lenvima® in combination with everolimus for advanced renal cell carcinoma (RCC)

/PRNewswire/ -- Novartis Pharmaceuticals Corporation today announced an agreement with Eisai Inc. to collaborate on commercial and certain medical affairs activities in the United States (US) to co-promote Lenvima* (lenvatinib) capsules used in ...
 TickerTech.com1 month ago

Colombia Threatens to Override Novartis's Patent on Gleevec

By Kejal Vyas BOGOTÁ -- Colombia's government will override Novartis's patent on a cancer medication by the end of May and open it up to generic manufacturers unless the Swiss pharmaceutical giant accepts a price cut, the country's health minister ...
 4 Traders2 months ago

Novartis to present pivotal data in hematologic and solid tumor cancers at 2016 ASCO Annual Meeting

/PRNewswire/ -- Novartis will highlight the strength of its oncology research programs at the upcoming 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO), being held June 3-7 in Chicago. Data will demonstrate advances across ...
 TickerTech.com2 months ago

MONALEESA-2 trial of Novartis' LEE011 (ribociclib) stopped due to positive efficacy results at interim analysis in HR+/HER2- advanced breast cancer

Novartis International AG / . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement. Independent Data Monitoring Committee recommends stopping the trial early as it met ...
 Bloomberg2 months ago MONALEESA-2 trial of Novartis LEE011 (ribociclib) stopped due to positive efficacy results at interim analysis in HR+/HER2- advanced breast cancer  PharmaVOICE2 months ago
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less